New indication positions Repatha as an option for high-risk adults with elevated LDL cholesterol and no prior cardiovascular ...

Under terms of the deal, Gilgamesh could receive up to $1.2 billion as bretisilocin progresses through clinical development ...

The FDA suspended Valneva’s U.S. license for its chikungunya vaccine Ixchiq due to serious safety concerns, multiple ...

BeOne Medicines entered a deal worth up to $950 million with Royalty Pharma selling its rights to global sales royalties of ...

The CDC appointed Retsef Levi, a vocal critic of mRNA Covid-19 vaccines, to lead its Covid-19 immunization workgroup, a panel ...

The science behind NAMs is evolving rapidly, offering innovative, ethically motivated approaches that can enrich mechanistic ...

Shiladitya Sengupta, founder, Vyome Therapeutics, explains how the company’s strong ties in India’s biotech and healthcare ...

Michael Grosberg, vice president of product management, spoke with Pharmaceutical Executive about direct-to-consumer sales ...

Regeneron Pharmaceuticals announced FDA extended review timelines to Q4 2025 for two regulatory submissions related to Eylea ...

Dawnzera is the first and only RNA-targeted prophylactic therapy to be approved for hereditary angioedema in adults and ...

The move is likely part of the company’s goal to reduce costs as it faces increased competition in the GLP-1 space.

Pfizer's inclacumab fails Phase III study for sickle cell disease, disappointing the community while the company remains ...